OMUFA Facility-Fee Registry Workspace

Analysis

OMUFA Facility-Fee Registry Workspace

1. Title

OMUFA Facility-Fee Registry Workspace for Small OTC Monograph Operators

2. One-line thesis

Build a consultant-first workspace that maps OTC monograph facilities, owners, CMOs, product/ingredient dependencies, SPL business-operation qualifiers, fee-liable status, payment evidence, and FDA list status so small OTC manufacturers and private-label brands avoid public arrears, misbranding exposure, and annual fee surprises.

3. ICP

Primary buyer: boutique FDA regulatory consultancies, U.S. agents, and OTC compliance service providers managing multiple small OTC monograph clients.

Secondary buyer: small OTC monograph manufacturers, contract manufacturers, private-label operators, sunscreen/personal-care OTC brands, and foreign OTC manufacturers selling into the U.S.

Best initial wedge: consultants with 10-100 client facilities/products who already coordinate eDRLS/SPL registration, labeler codes, annual renewal, U.S. agent records, and user-fee payment evidence in spreadsheets, inboxes, and client portals. They feel the pain earlier than single-facility manufacturers because a missed CMO, wrong qualifier, stale registration, or unpaid vendor facility can put many downstream product listings at risk.

4. Hard-fact grounding

OMUFA is not a vague compliance newsletter topic; it is a recurring, dollar-denominated operational workflow.

• FDA’s OMUFA page says FDA updated the OMUFA arrears and paid-facilities lists on May 11, 2026, and announced FY 2026 OTC monograph facility-fee rates in a March 18, 2026 Federal Register notice.

• The FY 2026 Federal Register notice says the facility fee applies to each facility identified as an OTC monograph drug facility during the fee-liable period from January 1, 2025 through December 31, 2025. It distinguishes full MDF fees from reduced CMO fees, and states FY 2026 fees are due June 1, 2026 if appropriations timing holds.

• FY 2026 fee rates are material for small operators: $19,188 for an MDF facility and $12,792 for a CMO facility, effective October 1, 2025 through September 30, 2026.

• FDA guidance defines a CMO facility as an OTC monograph drug facility where neither the owner nor an affiliate sells the OTC monograph drug produced there directly to U.S. wholesalers, retailers, or consumers. That makes ownership/affiliate/sales-channel mapping central, not optional.

• FDA guidance defines an OTC monograph drug facility around a foreign or domestic entity at one geographic location engaged in manufacturing or processing the finished dosage form. It excludes some activities such as testing, clinical-research supplies, and outer-packaging-only multipack creation, which creates classification edge cases.

• FDA’s FY 2025 SBIA slides say SPL business-operation qualifiers help FDA determine whether a facility is subject to OMUFA facility fees. The slides list qualifier codes including C131708 for human OTC monograph manufacturing and C170729 for contract manufacturing for human OTC monograph drugs produced under a monograph, including operations such as analysis, pack, label, repack, and relabel.

• FDA’s eDRLS instructions say annual registration renewal must occur between October 1 and December 31 each year, and that users create/submit establishment-registration SPL documents and save copies of submissions.

• FDA says registration/listing data is submitted electronically using SPL format and is used for inspections, postmarket surveillance, recalls, supply-chain resiliency, counterterrorism, and more.

• FDA’s arrears-list notice says if a facility does not pay within 20 calendar days of the due date, FDA places it on a public arrears list; all OTC monograph drugs produced at that facility, or containing an ingredient manufactured there, are deemed misbranded; and OMORs/related meeting requests from persons or affiliates in arrears will not be accepted.

• FDA’s fee FAQ shows the actual payment workflow: create an OMUFA Facility Fee Cover Sheet in FDA’s User Fee System, receive a PIN/cover-sheet number, then pay via Pay.gov, credit card/e-check, or wire transfer with the unique cover-sheet number. It also says fees not received within 30 calendar days after due date are treated as a U.S. Government claim subject to federal collection activity.

Product implication: a useful product does not need to replace CDER Direct, ESG, SPL authoring, Pay.gov, or FDA’s public lists. It needs to be the system of record before and after those systems: facility inventory, classification rationale, client/vendor responsibility matrix, evidence vault, deadline control, status reconciliation, and exception handling.

5. Pain evidence and buyer language

The strongest pain signal is a combination of public enforcement mechanics plus industry commentary repeating the operational warning.

Buyer-language signals:

• FDA’s arrears notice explicitly tells firms to “seek verification from your business partners that all applicable fees have been received in full.” That sentence is the product wedge: brands and consultants need a business-partner verification workspace, not merely a reminder calendar.

• Lachman Consultants warned that firms required to pay OMUFA fees but failing to do so “may appear on the OMUFA Facility Arrears List,” and reminded readers that failure to pay causes FDA to find all OTC products misbranded. It repeated FDA’s verification language and told readers to “check the list carefully to avoid an unpleasant surprise.”

• FDA Law Blog’s 2021 arrears-list writeup noted that the first arrears list included several hundred facilities running over 70 pages, and that it likely included edge cases such as ceased facilities and hand-sanitizer-era registrations. That is exactly the kind of stale-registration / false-positive / wrong-owner cleanup problem a workspace can organize.

• Registrar Corp’s commercial explainer uses stark market language: missing the fee deadline or misunderstanding facility classification can put products on the public FDA Arrears List and create “operational paralysis.” It also emphasizes that fees are mandatory and not prorated or installment-based.

This is not abundant Reddit-style user pain, but regulatory operations rarely surface there. The better evidence is: high-dollar annual fees, public lists, misbranding consequences, service-provider warnings, and the need to verify business partners’ payment status.

6. What to build

A narrow “OMUFA fee-liable facility registry room” with five modules:

1. Facility inventory

• Facility name, FEI, DUNS/UEI-like identifiers, address, owner, affiliate relationships, U.S. agent, client/brand relationships.

• Facility type candidate: MDF, CMO, not subject, unknown.

• Facility activity mapping: manufacture, process, analyze, pack, label, repack, relabel, ingredient/finished-dose role.

• SPL qualifier tracker: C131708, C170729, and adjacent OTC qualifier codes, with who last confirmed them and when.

2. Fee-liability classifier

• A rules checklist based on FDA definitions: active during fee-liable period, finished dosage form, CMO direct-sales/affiliate test, ceased operations before cutoff, excluded activities.

• “Why we think this facility is fee-liable / not fee-liable” memo export.

• Confidence flag: clear, likely, unclear, counsel review.

3. Responsibility and verification matrix

• Who is expected to pay: facility owner, CMO, client/brand, consultant-managed payer, or unresolved.

• Downstream dependency map: which private-label products and monograph owners rely on a given CMO/API/finished-dose facility.

• Business-partner verification requests with due dates and evidence uploads.

4. Annual fee readiness and evidence vault

• FY-specific calendar: fee-liable period, Federal Register rate publication, cover-sheet/PIN creation, payment due date, 20-day arrears risk date, 30-day collection risk date, registration renewal window.

• Evidence: FDA cover sheet, PIN, Pay.gov receipt, wire confirmation, FDA correspondence, screenshots/export of paid-facility list status.

• Audit packet export for each client/facility.

5. FDA status reconciliation

• Manual or semi-automated import of FDA paid/arrears lists.

• Facility matching by name, FEI, DUNS, address, and fuzzy aliases.

• Exception queues: missing from paid list, present on arrears list, ambiguous match, wrong facility type, possible ceased facility, no payment evidence.

7. MVP shape

Weekend-buildable MVP:

• Multi-tenant consultant dashboard with clients, facilities, products, and contacts.

• CSV import/export for facility inventory.

• Simple rules-based fee-liability checklist with a generated rationale memo.

• FY 2026 readiness board: unknown, classified, cover sheet created, PIN received, paid, verified on FDA list, exception.

• Evidence upload fields and structured metadata for PIN/payment method/date/amount.

• Reminder emails to client contacts and vendors requesting payment verification.

• Manual FDA list upload: user drops the latest arrears/paid PDF/CSV or pasted table; app flags matches and mismatches.

• One-click “client packet” PDF/HTML: facilities, classifications, responsibilities, evidence, FDA status, open exceptions.

Avoid in v1:

• Full SPL authoring or ESG submission.

• Direct Pay.gov/FDA User Fee System integration.

• Legal advice or automated legal determination.

• Replacing enterprise RIM systems.

Positioning: “Not SPL software. Not legal advice. The operating room for OMUFA facility-fee readiness and partner verification.”

8. Willingness-to-pay hypothesis

Budget exists because users are already paying for FDA registration/listing help, U.S. agent services, SPL services, and regulatory consulting. OMUFA facility fees themselves are five-figure annual obligations, so a tool that prevents one misclassification, missed fee, public arrears event, or client fire drill can justify a few hundred dollars per month for consultants.

Likely pricing:

• Consultant starter: $149-$299/month for up to 25 facilities.

• Consultant pro: $499-$999/month for 100-300 facilities, client portals, branded packets, and list reconciliation.

• Manufacturer/private-label operator: $99-$249/month for one organization and vendor verification.

• Services add-on: $500-$2,000 annual OMUFA readiness cleanup package delivered by partner consultants.

The highest willingness-to-pay is probably not the smallest one-facility OTC brand. It is the consultant who can amortize the tool across multiple client accounts and sell “annual OMUFA readiness packets” as a service.

9. Current substitutes

• FDA systems: eDRLS/CDER Direct, SPL Xforms, ESG, FDA User Fee System, Pay.gov, FDA public paid/arrears lists. These are necessary systems of action but not a collaborative readiness workspace.

• Spreadsheets and SharePoint/Google Drive folders: common and cheap, but weak at responsibility mapping, year-over-year carryforward, evidence completeness, and fuzzy list reconciliation.

• Email chains: used for partner verification but hard to audit.

• Regulatory consultants: they already solve the problem manually; this product should sell to them first, not displace them.

• Enterprise RIM/SPL vendors and services: Reed Tech-style SPL/product-data services and large regulatory platforms can cover adjacent registration/listing workflows, but may be too broad or expensive for small OTC/private-label operators.

• Generic compliance/project-management tools: Asana, Monday, Airtable, Smartsheet, Veeva-lite setups. Flexible, but they lack FDA-specific fee-liability logic, qualifier vocabulary, and FDA list reconciliation.

10. Distribution wedge

Start with the consultants and service providers who publish OMUFA reminders and sell registration/listing help.

Outbound list:

• FDA registration/listing consultants.

• U.S. agent firms for foreign drug establishments.

• OTC/private-label regulatory consultants.

• SPL conversion/listing service providers.

• Sunscreen, oral-care, acne, antiseptic, dandruff, and first-aid OTC contract manufacturers.

• Cosmetic/personal-care manufacturers that also make OTC monograph products.

Lead magnet:

• “FY 2026 OMUFA Facility-Fee Readiness Checklist.”

• Free “arrears-list exposure scan”: upload/paste facilities; receive a match report and missing-evidence checklist.

• “CMO vs MDF classification worksheet” based on FDA definitions and the direct-sales/affiliate test.

Founder-sales script:

“Do you know which client products depend on a facility whose OMUFA payment you cannot independently verify? FDA specifically encourages business-partner verification. We turn that into a client packet before the arrears list drops.”

11. Risks and counterarguments

1. Market may be smaller than it looks. OMUFA is a narrow annual workflow, and many manufacturers may only think about it once per year.

2. Consultants may prefer billable manual work. The product must help them sell a repeatable readiness service, not reduce billable hours.

3. FDA data/list formats may be awkward. Public lists are PDFs/pages rather than clean APIs. V1 should support manual upload and fuzzy matching before promising automation.

4. Classification can become legal/regulatory advice. The product should produce structured rationale and counsel-review flags, not assert definitive legal conclusions.

5. Enterprise RIM incumbents can absorb large customers. The opportunity is in the SMB/consultant layer that does not want Veeva-scale deployment.

6. Annual urgency creates seasonal churn. Counter with year-round facility inventory, annual registration renewal, product/vendor dependency mapping, and evidence carryforward.

7. Prior adjacent report overlap. This opportunity should stay narrower than generic FDA registration/listing renewal: focus specifically on OMUFA facility-fee liability, owner/CMO responsibility, partner verification, payment evidence, and FDA paid/arrears status.

12. Scorecard

• Pain: 8/10 — five-figure fees, public arrears, misbranding consequences, partner verification, and consultant fire drills create real operational pain.

• Willingness to pay: 7/10 — consultants and U.S. agents can monetize readiness packets; single small brands may resist SaaS unless bundled with services.

• Reachability: 7/10 — FDA consultants, U.S. agent firms, SPL providers, and OTC contract manufacturers are searchable and often publish compliance content.

• MVP simplicity: 7/10 — CRUD, checklists, evidence vault, reminders, and manual list reconciliation are buildable; automated FDA integrations can wait.

• Competition: 6/10 — substitutes exist, but a narrow OMUFA fee-liability workspace is not obviously saturated.

• Overall: 7/10 — BUILD/MAYBE. Strong as a consultant-first compliance operations wedge; weaker as standalone self-serve SaaS for tiny manufacturers.

13. What might be wrong here?

The main uncertainty is buyer frequency. OMUFA facility-fee readiness is intense but seasonal; a standalone product may need to bundle adjacent annual registration renewal and listing certification evidence to earn year-round usage. Another uncertainty is data access: if FDA’s paid/arrears lists remain PDF-like and inconsistent, matching will require human review. Finally, the cleanest buyers may already have internal templates; the product must win by turning those templates into branded client packets, exception queues, and reusable annual workflows, not by being yet another checklist.

14. Sources

• FDA — Over-The-Counter Monograph Drug User Fee Program (OMUFA): https://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa

• Federal Register — Over-the-Counter Monograph Drug Facility Fee Rates for Fiscal Year 2026: https://www.federalregister.gov/documents/2026/03/18/2026-05276/over-the-counter-monograph-drug-facility-fee-rates-for-fiscal-year-2026

• FDA — OMUFA FY 2026 User Fees and Registration webinar page: https://www.fda.gov/drugs/news-events-human-drugs/otc-monograph-drug-user-fee-amendments-omufa-understanding-fy-2026-user-fees-and-registration

• FDA — Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program guidance PDF: https://www.fda.gov/media/162759/download

• FDA — OMUFA Facility Arrears List PDF: https://www.fda.gov/media/150585/download

• FDA — Other OMUFA Fee-Related Questions: https://www.fda.gov/industry/over-counter-monograph-drug-user-fee-program-omufa/other-omufa-fee-related-questions

• FDA — Electronic Drug Registration and Listing Instructions: https://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-drug-registration-and-listing-instructions

• FDA — Electronic Drug Registration and Listing System: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/electronic-drug-registration-and-listing-system-edrls

• FDA — SPL Xforms: https://www.fda.gov/industry/structured-product-labeling-resources/spl-xforms

• Lachman Consultants — Updated OMUFA Arrears List Published: https://www.lachmanconsultants.com/2025/06/updated-omufa-arrears-list-published/

• FDA Law Blog — FDA Publishes OMUFA Arrears List and Answers Fee-Related Questions: https://www.thefdalawblog.com/2021/06/fda-publishes-omufa-arrears-list-and-answers-fee-related-questions/

• Registrar Corp — What Is OMUFA? FDA Fees Guide For OTC Compliance: https://www.registrarcorp.com/blog/drugs/drug-regulations/what-is-omufa/